Kidney Disease

New Therapeutic Strategy in Chronic Kidney Disease

Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease’s progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania has found an aspect of CKD’s development that points to a promising new therapeutic strategy.

A release from the university quotes says Katalin Susztak, MD, PhD, an associate professor of Medicine in the Renal Electrolyte and Hypertension Division, as saying, “We found that a defect in energy production in affected kidney cells plays a key role in CKD development. Restoring the energy supply in these cells largely prevented signs of CKD in mouse models.”

In the study, published online in December 2014 advance of the print edition of “Nature Medicine”, Susztak and colleagues focused on a central feature of CKD: the “fibrosis” process. This is a pathological response to chronic kidney stress that includes an abnormal buildup of fibrous collagen, a loss of capillaries, a die-off of important kidney cells called tubular epithelial cells, and other changes that progressively reduce a kidney’s ability to filter the blood properly.

The researchers compared the patterns of gene activity in fibrotic and normal human kidney tissue samples. They found abnormal patterns in gene networks linked to inflammation and sharp drops in activity in gene networks that support energy metabolism in the fibrotic samples.

The fact that inflammation is a factor in CKD was already well known, so Susztak and her colleagues aimed their investigation at two types of energy metabolism—glucose oxidation and fatty acid oxidation — that seemed markedly reduced in the fibrotic samples.

“What we found is that the tubular epithelial cells preferentially use fatty acid oxidation as their energy source in normal conditions,” Susztak says. “Even when fatty acid metabolism drops in the context of CKD, these cells don’t switch to burning glucose for energy.”

Susztak’s team examined several mouse models of kidney fibrosis, and again found strikingly lower activity in genes that support fatty acid metabolism. The researchers also found strong hints that the loss of cellular fuel is a driver of the fibrosis process. In mouse models, the drop in fatty acid metabolism preceded the signs of fibrosis. In human tubular epithelial cells, artificially reducing fatty acid metabolism quickly brought about fibrosis-like signs, including the buildup of fat molecules (unspent fuel) and the deaths of many affected cells.

That fat buildup in kidney cells had been hypothesized to be a significant cause of cell death in CKD fibrosis. But Susztak showed with a mouse model of fat accumulation in tubular epithelial cells that the fat accumulation on its own had minimal impact. The more important factor in fibrosis was the loss of energy in the cells as fatty acid metabolism dropped.

The researchers also found evidence that the shutdown of fatty acid metabolism in tubular epithelial cells is caused in large part by the growth factor TGFβ. This factor is known to promote fibrosis and has been linked to high blood glucose levels, high blood pressure, and inflammation—all triggers of CKD.

Encouragingly, when Susztak’s team restored fatty acid metabolism in mouse models of kidney fibrosis using genetic techniques or compounds that boost the activity of fatty acid metabolism genes, the treatment prevented nearly all signs of fibrosis.

One of the compounds tested, fenofibrate, is an existing anti-cholesterol drug that activates a master switch gene, PPARA, for fatty acid metabolism. But fenofibrate could be problematic as a kidney disease drug, Susztak says, because it can distort the results of a standard test of kidney function. This side effect could impede the ability to evaluate the drug’s benefit, and more generally, could make it harder for doctors to monitor the progression of CKD in patients taking the drug.

“We hope to develop new compounds that are similar to fenofibrate, or that boost enzymes more specifically related to fatty acid metabolism,” she says. “In that way we might be able to greatly slow the progress of CKD.”

She and her colleagues are also trying to connect the newly revealed metabolic changes in CKD fibrosis to the epigenetic changes—alterations in the patterns of DNA markers that control gene expression in cells—that they described in a paper last year in “Genome Biology”.

Collaborating laboratories on the study included those of Kumar Sharma at the University of California, San Diego; James Pullman of the Montefiore Medical Center, New York; Erwin P. Bottinger of the Icahn School of Medicine at Mount Sinai; and Ira J. Goldberg of New York University’s Langone Medical Center.

Funding for Dr. Susztak’s research was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087635, R01DK076077) and the Diabetic Complications Consortium (DK076169).

you may also like

Recipes We

Khela88

Fancywin

Jita Ace

Betjili

https://betvisa1.org/

jeetbuzz লগইন

jeetwin app

baji999

winbuzz

betvisa login

winbuzz

six6s

babu88

marvelbet

krikya

mostplay

4rabet

leonbet

pin up

mostbet

all rummy app

Fastwin

Jitawin

R777

Bhaggo

PBC88

Winbdt

Crickex

Betjee

Glory Casino

Jita Bet

Melbet

Jwin7

Jita Ace

Krikya

Six6s

Betjili

Mostplay

Jeetbuzz

Jeetwin

Mostbet

Baji999

Marvelbet

Betvisa

Mcw

Nagad88

Babu88

Jaya9

babu88 babu88 jeetwin abbabet nagad88 marvelbet melbet mostbet six6s crickex mcw casino baji999 betvisa krikya mostplay crazy time jeetbuzz 79king1 good88 11bet xoso66 nohu78 xin88 nohu90 v9bet fastwin betvisa
jeetbuzz
babu88
babu888
jeetwin
nagad88
jaya9
khela88
mostplay
baji999
abbabet
1xbet 12bet marvel bet 91 club betvisa login baji999 sky247 gugobet lotus365 yolo247 bsport loto188 bsport site 8day xoso66 v9bet rummy deity yono rummy new88 typhu88 jeetbuzz dafabet lotus365 bet88 v9bet đăng nhập thienhabet 188bet link dafabet login betvisa king567 yolo247 login 1xbet login 24betting 91club crickex kubet new88 hi88 jun88 w88 shbet mksports 33win f8bet 123b fb88 vn88 mu88 five88 bk8 w388 gnbet mcw casino thienhabet sodo casino cmd368 bsport eubet sbobet mibet cmd368 Faridabad Satta Satta King 786 Dafabet betvisa yono rummy rummy apk

alo789

https://metalwave.com.mx/app/

https://meisetio.com/wp-includes/js/jquery/ai/index.php?tunnel=alo-789

https://purneauniversity.ac.in/assets/js/mk/?tunnel=baji999

fastwin

fastwin

winzo

winzo

futemax

Kèo nhà cái

bongdadzo

Tỷ số bóng đá

KQBD

Kết quả bóng đá

rummy nabob

hi88

8day

97win

n88

red88

king88

j88

i9bet

good88

nohu78

99ok

bet168

satta king

satta matta matka

Canais Play

ALO789

yono rummy
rummy deity
rummy nabob
rummy wealth
daman games
jeetbuzz
yolo247
baji999
rummy gold
188bet
v9bet
789bet
crickex
1xbet
thienhabet
c54
sky88
33win
79king
kubet
shbet
good88
3king
nohu
lucky88
97win
xoso66
xin88
daga88
yolo247
jeetbuzz
betvisa
jeetwin
baji999
nagad88
babu88
mostplay
babu888
jaya9
khela88
jaya9
khela88
jeetbuzz
betvisa
abbabet
babu88
babu888
jeetwin
nagad88
jaya9
joya 9
khela88
mostplay
marvelbet
baji999

Sponsored From Malaysia

말레이시아에서 후원